- Details
- Diane Newman hosts Avanti Rangnekar to discuss research examining pelvic floor dysfunction and dyspareunia in elite female athletes at the University of Pennsylvania. The study investigates whether rigorous athletic training contributes to increased incidence of pelvic floor dysfunction, particularly focusing on provoked vestibulodynia (PVD) and painful intercourse among NCAA Division I athletes i...
|
- Details
- Yair Lotan joins Zachary Klaassen to discuss the 36-month follow-up data of nadofaragene firadenovec for BCG-unresponsive bladder cancer. The phase 3 trial evaluates the long-term efficacy and safety of nadofaragene, an intravesical adenovirus vector administered every three months, in patients with carcinoma in situ and papillary disease. While initial response rates are promising, the discussion...
|
- Details
- Avanti Rangnekar joins Diane Newman to discuss research examining the relationship between smoking and urinary urgency in women. The study, conducted through ResearchMatch, analyzes data from over 1,700 community-based women to evaluate both current smoking status and cumulative pack-year history's impact on overactive bladder symptoms. The findings reveal that current smokers face significantly h...
|
- Details
- Ali Nasrallah discusses the BRAVO study (Bladder Cancer Recurrence Analysis in Veterans and Outcomes). The study examines the real-world impact of blue light cystoscopy versus white light cystoscopy in non-muscle invasive bladder cancer patients within the VA healthcare system. Using data from 1997 to 2021, the research demonstrates significantly reduced recurrence rates at three years with blue l...
|
- Details
- Zachary Klaassen speaks with Lisa Lowenstein about transitioning men from active surveillance to watchful waiting in prostate cancer management. Dr. Lowenstein shares insights from her research on patient and clinician perspectives, highlighting the challenges of convincing men to reduce their monitoring intensity. She describes developing a shared decision-making intervention to help guide these...
|
- Details
- Brian Rini joins Pedro Barata to discuss the updated results of the Phase 3 LITESPARK-005 trial. The study, which led to belzutifan's approval in December 2023, compares belzutifan to everolimus in refractory clear cell RCC patients who previously received PD-1/PD-L1 and VEGF-TKI therapy. While the trial demonstrates improved progression-free survival and response rates with belzutifan, overall su...
|
- Details
- Evan Yu joins Zachary Klaassen to discuss the results of the ARROW trial. The study evaluates Iodine-131-LNTH-1095, a novel PSMA radioligand therapy, in combination with enzalutamide versus enzalutamide alone for metastatic castration-resistant prostate cancer patients who previously received abiraterone. While the trial meets its primary endpoint with significantly higher PSA decline rates in the...
|
- Details
- Silke Gillessen joins Neeraj Agarwal to discuss the results of the STAMPEDE trial's metformin arm. The phase 3 trial evaluates the addition of metformin to androgen deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer. While the primary endpoint of overall survival is not met, the study reveals significant improvements in metabolic parameters, including reduced w...
|
- Details
- Martin Miner discusses a Wall Street Journal article highlighting concerns about testosterone clinics and replacement therapy. Dr. Miner explains who makes appropriate candidates for testosterone therapy, emphasizing the importance of both low levels and clinical symptoms, while cautioning against the trend of younger men seeking treatment purely for body image concerns. He discusses how testoster...
|
- Details
- Zachary Klaassen speaks with Sarah Psutka about cognitive resilience in bladder cancer care. Dr. Psutka explains how cancer treatment, from surgery to chemotherapy, can significantly impact cognitive function, with up to a third of patients experiencing persistent postoperative cognitive dysfunction. She emphasizes the shift from focusing solely on physical frailty to understanding patients' compl...
|